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AbstrACt
Objectives To evaluate the effect of interpregnancy body 
mass index (BMI) change on pregnancy outcomes, including 
large-for-gestational-age babies (LGA), small-for-gestational-
age babies (SGA), macrosomia, gestational diabetes mellitus 
(GDM) and caesarean section (CS).
Design Systematic review and meta-analysis of 
observational cohort studies.
Data sources Literature searches were performed across 
Cochrane, MEDLINE, EMBASE, CINAHL, Global Health and 
MIDIRS databases.
study selection Observational cohort studies with 
participants parity from 0 to 1.
Main outcome measures Adjusted ORs (aORs) with 
95% CIs were used to evaluate the association between 
interpregnancy BMI change on five outcomes.
results 925 065 women with singleton births from parity 
0 to 1 were included in the meta-analysis of 11 studies 
selected from 924 identified studies. A substantial increase 
in interpregnancy BMI (>3 BMI units) was associated with 
an increased risk of LGA (aOR 1.85, 95% CI 1.71 to 2.00, 
p<0.001), GDM (aOR 2.28, 95% CI 1.97 to 2.63, p<0.001), 
macrosomia (aOR 1.54, 95% CI 0.939 to 2.505) and CS 
(aOR 1.72, 95% CI 1.32 to 2.24, p<0.001) compared with 
the reference category, and a decreased risk of SGA (aOR 
0.83, 95% CI 0.70 to 0.99, p=0.044). An interpregnancy BMI 
decrease was associated with a decreased risk of LGA births 
(aOR 0.70, 95% CI 0.55 to 0.90, p<0.001) and GDM (aOR 
0.80, 95% CI 0.62 to 1.03), and an increased risk of SGA (aOR 
1.31, 95% CI 1.06 to 1.63, p=0.014). Women with a normal 
BMI (<25kg/m2) at first pregnancy who have a substantial 
increase in BMI between pregnancies had a higher risk of 
LGA (aOR 2.10, 95% CI 1.93 to 2.29) and GDM (aOR 3.10, 
95% CI 2.74 to 3.50) when compared with a reference than 
women with a BMI ≥25 kg/m2 at first pregnancy.
Conclusions Gaining weight between pregnancies increases 
risk of developing GDM, CS and LGA, and reduces risk of 
SGA in the subsequent pregnancy. Losing weight between 
pregnancies reduces risk of GDM and LGA and increases risk 
of SGA. Weight stability between first and second pregnancy 
is advised in order to reduce risk of adverse outcomes.
trial registration number CRD42016041299.
IntrODuCtIOn  
The associations between high pregravid 
body mass index (BMI) and maternal and 
neonatal complications are well established1; 
complications include gestational diabetes 
mellitus (GDM), caesarean section (CS), 
pre-eclampsia, macrosomia, prematu-
rity and stillbirth.2 These outcomes are of 
public health importance because they add 
to the disease burden of women and their 
infants,thereby increasing healthcare costs.3 
Mirroring the trend of the global obesity 
epidemic (more than half of all women of 
reproductive age in the UK are overweight 
or obese),4 the prevalence of all these preg-
nancy complications has risen, as has the 
focus on maternal weight management as a 
means to improve the health of women and 
their children.
Previous studies have investigated the effect 
and impact of increased weight on adverse 
outcomes at all stages of the periconceptional 
period.5 Lifestyle and medical interventions 
during pregnancy have shown little effect 
on pregnancy outcomes.6 In the meantime, 
interpregnancy care is aimed at optimising 
outcomes of women and their future babies.7 
But standards are lacking8 and, owing to the 
paucity of literature, systematic reviews and 
strengths and limitations of this study
 ► We believe this to be the first meta-analysis com-
pleted on the topic of interpregnancy weight change 
and its effect on five adverse pregnancy outcomes.
 ► A large sample size of 925 065 women was collect-
ed from 11 well-adjusted population-based obser-
vational studies, with two methods used to assess 
the quality of the studies.
 ► Sensitivity analysis was conducted to remove 
low-quality research, which did not change the di-
rection of effect for any outcome.
 ► Limitations included limited generalisability, as the 
research was conducted in high-income countries 
and only in women from parity 0 to 1.
 ► Furthermore, high heterogeneity persisted after sen-
sitivity analysis, and additional confounders (such as 
breast feeding) could affect the results.
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meta-analysis, any effect of interpregnancy care on preg-
nancy outcomes remains nascent.8–10
Despite a plausible rationale for weight management as 
part of interpregnancy planning, a knowledge gap exists 
among healthcare providers and women of reproductive 
age of the impact of weight change between pregnancies. 
Interpregnancy weight change is defined as the difference 
in BMI between first and second pregnancy recorded at 
the first antenatal visit.11 While the number of relevant 
studies has expanded in recent years, no meta-analysis 
has been attempted. The aim of this meta-analysis was to 
address this gap by examining the association between 
interpregnancy weight change and the most preva-
lent associated adverse pregnancy outcomes: GDM, CS, 
large-for-gestational-age babies (LGA) and small-for-ges-
tational-age babies (SGA) in the next pregnancy (see 
table 1 for definitions). Where possible, the data were 
divided according to maternal BMI <25 and ≥25 kg/
m2, in order to address effects of interpregnancy weight 
change in the overweight/obese population compared 
with women with a normal BMI. Only the first two succes-
sive pregnancies were assessed in order to minimise 
confounding due to any effects of parity on pregnancy 
outcome.
MethODs
Protocol and registration
The study was registered in The International Prospec-
tive Register of Systematic Reviews (PROSPERO) 
(CRD42016041299). The criteria outlined in the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement and the Meta-anal-
ysis of Observational Studies in Epidemiology (MOOSE) 
checklist was adhered to.
Information sources
Electronic databases including CINAHL, EMBASE, 
MEDLINE, the Cochrane Database of Systematic Reviews, 
MIDIRS and Global Health were searched from January 
1990 to January 2017. Searches were limited to studies in 
humans. There were no language constraints. In addi-
tion, references from bibliographies and citations were 
manually searched. A grey literature search was run until 
1 January 2017 across the following clinical trials regis-
tries: TRIP Database, EThOS, WHO International Clin-
ical Trials Registry Platform Search Portal and the EU 
Clinical Trials Register.
search strategy
A search strategy was developed for MEDLINE (see 
table 2) and adapted for other databases. The following 
combination of MeSH terms and free text were used: 
interpregnancy, prepregnancy, weight gain, weight loss, 
neonatal outcomes and pregnancy complications.
Outcome measures
Five of the most prevalent adverse outcomes were chosen 
as outcomes of interest for this review. These included 
LGA, SGA, macrosomia, CS and GDM (defined in 
table 1). Gender-specific birth weight charts were used in 
the research for LGA and SGA birth weights. It should be 
noted that throughout this paper, BMI will be referred to 
in groups according to the WHO and National Institute for 
Health and Care Excellence (NICE) BMI classifications.12
study selection
Observational studies such as cohort and case-control 
studies were included, with studies limited to humans. 
Only singleton births from parity 0 to 1 were included. 
Studies that were restricted to women with previous 
diabetes diagnoses were excluded, as were studies 
Table 1 Definitions of maternal and fetal outcomes used 
throughout this review
Outcome Definition
Large for gestational 
age
A baby with birth weight ≥90th 
percentile of all babies with same 
gestational age.2
Small for gestational 
age
A baby with birth weight <10th 
percentile of all babies with same 
gestational age.2
Macrosomia Birth weight of >4000 g.50
Caesarean section Surgical incision into abdominal and 
uterine wall to achieve delivery of 
the baby.51 Only emergency CS was 
considered in this study.
Gestational diabetes 
mellitus
Any degree of glucose intolerance 
with onset or first recognition during 
pregnancy.52
Table 2 Search strategy for MEDLINE
1 exp birth intervals/
2 (interpregnan* or inter-pregnan* or (birth adj interval) 
or (between adj pregnan*) or (successive adj pregnan*) 
or interbirth or (pregnan* adj spacing) or (pregnan* 
adj interval) or (birth adj spacing) or interdelivery or 
(consecutive adj pregnan*) or (following adj pregnanc*) 
or (subsequent adj pregnan*)).mp.
3 1 or 2
4 ((body adj weight) or body mass index or BMI or (weight 
adj change) or (weight adj los*) or (weight adj decrease) 
or (weight adj gain*) or (weight adj increase) or (BMI 
adj change) or (body adj mass adj index) or (body adj 
weight adj change)).mp.
5 ((pregnancy adj complication) or (f?etal adj outcome) 
or (pregnancy adj outcome) or (adverse adj outcome) 
or macrosomia or large for gestational age or LGA or 
large-for-gestational-age or (birth adj weight) or SGA or 
small for gestational age or small-for-gestational-age 
or GDM or (gestational adj diabetes) or c-section or 
(c?esarean adj section).mp.
6 3 and 4 and 5
7 Limit 6 to humans
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published as conference abstracts, reviews, pharmacolog-
ical or surgical interventions for weight loss, case reports 
or unpublished trials. Citations found through database 
searches and other searches such as browsing bibliogra-
phies were combined and duplicates excluded.
Data collection and extraction
The Cochrane Good Practice Data Extraction Form was 
used for extracting relevant data of each study. Raw data 
were collected where available or calculated from the 
information given. Adjusted ORs (aORs) and 95% CIs 
were extracted from all papers. Additional information 
collected from studies included: first author’s name and 
year of publication, study design, setting, study period, 
sample size, outcomes, inclusion/exclusion criteria, 
quality assessment and population demographics and 
factors that each study adjusted for (including age, race, 
socioeconomic status, interpregnancy interval, previous 
maternal disease, gestational weight gain and education 
level).
To study whether association between change in body 
weight and adverse outcomes differed, study groups were 
classified as ‘substantial increase in BMI’, ‘moderate 
increase in BMI’ and ‘decrease in BMI’. These groups were 
defined as BMI increase of >3 units (substantial increase), 
BMI increase between 1 and 3 units (moderate increase) 
and BMI decrease >1 unit (decrease). If an outcome 
had small number of studies, substantial increase and 
moderate increase were combined as ‘increase in BMI’. 
In studies that reported results based on the WHO clas-
sification, women who changed from normal weight to 
underweight were considered as part of the BMI decrease 
category, and weight change from normal to obese repre-
sented a substantial increase in BMI. These studies were 
used as part of subgroup analyses (initial BMI >25 kg/
m2 ‘overweight/obese’ or BMI <25 kg/m2 ‘normal’) and 
converted into substantial (normal to obese), moderate 
(normal to overweight) and decrease in BMI groups 
(normal to underweight), respectively.
Interpregnancy weight change was defined as the 
prepregnancy BMI before first pregnancy to the prepreg-
nancy BMI before second pregnancy. For each outcome, 
the association of BMI change on adverse pregnancy 
outcome was compared with the reference category, 
which was defined as women who remained within their 
BMI category or their BMI changed by up to 2 units in 
either direction.
Two investigators (SM, OS) independently performed 
the literature search, assessed the eligibility and quality of 
the retrieved papers and performed the data extraction. 
The two authors compared the results and disagreements 
were resolved by a third reviewer (EO-N).
risk of bias assessment
To assess the quality of the studies, a modified Newcas-
tle-Ottawa Scale (NOS) and a Cochrane analysis of bias 
were performed. Sensitivity analysis was performed by 
removing studies with a NOS score (≤4 stars) or a high 
level of bias (<3 points) according to the Cochrane 
analysis.
statistical analysis
Forest plots were made for each outcome to assess 
overall effect size and heterogeneity using Stata SE V.14 
(StataCorp, College Station, Texas, USA). Random-effects 
model was used to account for variability across studies. 
Study weight was calculated using the inverse variance 
method. Data were pooled and heterogeneity assessed 
with the I2 statistic, with a high heterogeneity defined 
as being over 50%. Results were considered statistically 
significant if p value was <0.05. Sensitivity analysis was 
performed by removing low-quality studies. Analysis was 
then repeated and results compared.
role of funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation or writing of the report. 
The authors had full access to all data in the study and 
had final responsibility for the decision to submit for 
publication.
Patient and public involvement
No patients were involved in setting the research question 
or the outcome measures, and no patients were involved 
in developing plans for design or implementation of the 
study. Furthermore, no patients were asked to advice 
on interpretation or writing up of results. Since this 
meta-analysis used aggregated data from previous trials, 
it is unable to disseminate the results of the research to 
study participants directly.
results
literature search results
Results from the literature search came back with 11 
studies to be included in the qualitative synthesis. The 
2009 PRISMA flow diagram can be seen in figure 1, 
showing the process of study selection.
study characteristics
Study characteristics can be found in table 3. Out of 
the studies, one study was from Belgium,13 seven were 
from the USA,14–20 two from Scotland21 22 and one from 
Sweden.23 Four papers studied GDM, five papers studied 
LGA, four papers studied SGA, one paper studied macro-
somia and six papers studied CS (table 3). All studies 
presented their data in aORs. Seven out of the 11 studies 
used self-reports to record prepregnancy weight and 
height. All studies adjusted for confounding variables 
such as age, race, education and marital status with 
most studies also adjusting for interpregnancy interval, 
smoking, socioeconomic status, alcohol use, country of 
birth and maternal illness. About half of the prospec-
tive studies were community-based, using data found 
from national or state databases while other studies used 
hospital data.
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Data quality
Data quality was assessed using a modified NOS24 as well as 
a Cochrane tool of assessing bias in studies.25 The criteria 
for allocating stars (out of a total of 7 stars) awarded to 
each study according to this NOS criteria can be found 
in online supplementary appendix table 1. The results of 
these data quality assessment can be seen in online supple-
mentary appendix 1, tables 2-3. The exposed cohort was 
defined as women with a change in interpregnancy BMI, 
while the non-exposed cohort was defined as women who 
remained within their original BMI category or their 
BMI changed by up to 2 units in either direction. Despite 
authors attempting to adjust for the missing data, only 
five studies assessed the problem of missing data and anal-
ysed if this missing data were significant. One study13 did 
not report data unless it was statistically significant, giving 
rise to a possible high risk of reporting bias. Self-reported 
assessment of exposure as well as incomplete data are 
the two greatest sources of bias in the studies. The total 
score shown in online supplementary appendix 1, table 
3 allows for comparison of Cochrane analysis of bias and 
NOS. These two assessments show good agreement; good 
quality studies tended to have a lower risk of bias.
Outcomes
A decrease in BMI (>1 BMI unit) was associated with a 
33% reduction in LGA births (aOR 0.70, 95% CI 0.55 to 
0.90, I2=82.0%), while a moderate increase in BMI is asso-
ciated with a 43% higher risk of LGA birth compared with 
the reference category (aOR 1.43, 95% CI 1.29 to 1.59, 
I2=57.4%). A significant increase in BMI, defined as being 
an increase of over 3 units, had the highest risk of LGA 
birth (aOR 1.85, 95% CI 1.71 to 2.00, I2=0%) (figure 2). 
Z-values and p values for these results (see online 
Figure 1 The 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram showing results of 
literature search.
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supplementary appendix 2, table 1) show that all three 
pooled estimates were statistically significant (p<0.05).
Only one study included macrosomia as an outcome.13 
Their results showed that decrease in BMI had a reduced 
risk of macrosomia (aOR 0.5, 95% CI 0.35 to 0.71), with 
a substantial increase in BMI associated with a higher risk 
of macrosomia (aOR 1.537, 95% CI 0.939 to 2.505). It 
should be noted that this paper also reported data for 
low birth weight (<2500 g) and found that a decrease in 
BMI >−1 unit was associated with aOR 2.22 (95% CI 1.41 
to 3.51).
A decrease in BMI (>1 BMI unit) resulted in a decreased 
risk of GDM (aOR 0.80, 95% CI 0.62 to 1.03, I2=51.1%). 
A moderate increase in BMI was associated with a 56% 
increased risk of GDM (aOR 1.70, 95% CI 1.48 to 1.96, 
I2=0.0%). A substantial increase in BMI (>3 units) was 
similarly associated with a high risk of GDM (aOR 2.28, 
95% CI 1.97 to 2.63, I2=0.0%) (figure 3). P values for these 
pooled results were statistically significant for moderate 
(p<0.001) and substantial increase in BMI (p<0.001) and 
risk of GDM (see online supplementary appendix 2, table 
1). P values for decrease in BMI was not statistically signif-
icant (p>0.05).
No association was observed between a decrease in 
BMI and risk of CS births (aOR 0.97, 95% CI 0.89 to 
1.05, I2=0.0%), while a moderate increase and substan-
tial increase in BMI were associated with higher risks 
of CS (aOR 1.16, 95% CI 1.06 to 1.26, I2=53.5% and 
aOR 1.72,95% CI 1.32 to 2.24, I2=89.1%, respectively) 
(figure 4). Both moderate and substantial increase in 
BMI were statistically significant (p<0.05) (see online 
supplementary appendix 2, table 1).
A decrease in BMI (>1 BMI unit) was associated with 
an increase in SGA births (aOR 1.31, 95% CI 1.06 to 
1.63, I2=53.5%), while an increase in BMI was associ-
ated with a decreased risk of SGA births compared with 
the reference category (aOR 0.83, 95% CI 0.70 to 0.99, 
I2=56.8%) (figure 5). Both these results are statistically 
significant (see online supplementary appendix 2, table 
1).
Outcomes grouped by bMI before first pregnancy
Some studies divided women into women with a BMI 
of <25 kg/m2 at their first pregnancy (normal) and 
women with a BMI >25 kg/m2 at their first pregnancy 
(overweight/obese).
Figure 2 Forest plot showing change in interpregnancy weight and the risk of large-for-gestational-age (LGA) births in all 
women relative to reference category (decrease in body mass index (BMI) defined as >−1 unit, moderate increase 1–3 units and 
substantial increase >3 units, reference category remained in same BMI category or changed by up to −2 to +2 units). aOR, 
adjusted OR.
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Women of normal BMI (<25 kg/m 2) at beginning of 
first pregnancy are at a higher risk of LGA babies if they 
have a substantial increase of BMI (OR 2.10, 95% CI 1.93 
to 2.29, I2=7.7%) compared with women who had an over-
weight/obese BMI (≥25 kg/m2) at the beginning of first 
pregnancy (OR 1.69, 95% CI 1.37 to 2.09, I2=86.2%) (see 
online supplementary appendix 2, table 2 for statistical 
significance). The same trend is apparent in a moderate 
increase of BMI (an increase of between 1 and 3 units) 
(see online supplementary appendix 3, figure 3-4).
Women of normal BMI (<25 kg/m 2) at beginning of 
first pregnancy are at a higher risk of GDM if they have 
a substantial increase of BMI (OR 3.10, 95% CI 2.74 to 
3.50, I2=0.0%) compared with women who had an over-
weight/obese BMI (≥25 kg/m2) at the beginning of first 
pregnancy (OR 1.82, 95% CI 1.34 to 2.48, I2=51.6%) 
(see online supplementary appendix 3, figure 3-4). The 
same trend is apparent in a moderate increase of BMI.
Women of normal BMI (<25 kg/m2) at beginning of 
first pregnancy are at a higher risk of CS if they have a 
substantial increase of BMI (OR 1.70, 95% CI 1.34 to 
2.16, I2=87.7%) compared with women who had an 
overweight/obese BMI (≥25 kg/m2) at the beginning of 
first pregnancy (OR 1.52, 95% CI 0.84 to 2.75, I2=78.0%) 
(see online supplementary appendix 3, figure 5-6). The 
same trend is apparent in a moderate increase of BMI. 
However, the CIs of these two ORs overlap and therefore 
the statistical significance can be questioned.
One study20 found that women of normal BMI (<25 kg/
m2) who lose weight during the interpregnancy interval 
are at a similarly strong risk of SGA (aOR 1.76, 95% CI 
1.35 to 2.28) compared with women of an overweight/
obese BMI (>25 kg/m2) who lose weight (aOR 1.73, 95% 
CI 1.18 to 2.54).
sensitivity analysis
Sensitivity analysis was assessed by removing studies that 
had a high level of bias (<3 on the Cochrane analysis of 
bias) or were of low quality according to NOS (≤4 stars). 
Removal of low-quality studies made limited difference to 
the results and the direction of effect remained the same. 
For LGA in women with a BMI <25 kg/m2, results before 
removal of studies included decrease in BMI (aOR 0.65, 
95% CI 0.49 to 0.86, I2=79.9%), moderate increase in 
Figure 3 Forest plot showing change in interpregnancy weight and the risk of gestational diabetes mellitus (GDM) in all 
women relative to reference category (decrease in body mass index (BMI) defined as >−1 unit, moderate increase 1–3 units and 
substantial increase >3 units, reference category remained in same BMI category or changed by up to −2 to +2 units). aOR, 
adjusted OR.
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BMI (aOR 1.62, 95% CI 1.54 to 1.71, I2=0%) and substan-
tial increase (aOR 2.10, 95% CI 1.93 to 2.29, I2=7.7%). 
After sensitivity analysis, heterogeneity for each of these 
groups decreased (see online supplementary appendix 4, 
table 1).
heterogeneity
Generally, an I2 value of 25% is considered low, 50% 
moderate and 75% high.26 This value is thought to reflect 
the proportion of between-study variance not explained 
by sampling. When pooling results from population-based 
observational studies and the type of research used in this 
paper, it is impossible to control all possible confounders 
which is why a certain level of heterogeneity could be 
expected. As Higgins comments, if the predefined eligi-
bility criteria and data are correct, any level of heteroge-
neity is acceptable, given that the authors can analyse the 
heterogeneous studies appropriately.27 Analysis in this 
paper included random-effects analysis and sensitivity 
analysis. Further analysis of heterogeneity in this review 
is warranted; however, the Cochrane handbook recom-
mends that meta-regression should not be completed 
if there are fewer than 10 studies in a meta-analysis.28 
Furthermore, it has been stated that this corresponds to 
10 studies for each covariate in meta-regression.29 Due to 
this, the sources of heterogeneity will instead be discussed 
in limitations.
DIsCussIOn
Major findings
This study found that an interpregnancy BMI decrease is 
associated with a reduced risk of LGA births (aOR 0.70, 
95% CI 0.55 to 0.90, p<0001), reduced risk of macrosomia 
(aOR 0.50, 95% CI 0.35 to 0.71) and GDM (aOR 0.80, 
95% CI 0.62 to 1.03) and an increased risk of SGA (aOR 
1.31, 95% CI 1.06 to 1.63, p=0.01) compared with refer-
ence category of women who retained BMI. A substan-
tial increase in interpregnancy BMI (>3 BMI units) is 
associated with an increased risk of LGA (aOR 1.85, 
95% CI 1.71 to 2.00, p<0.001), GDM (aOR 2.28, 95% 
CI 1.97 to 2.63, p<0.001), CS (aOR 1.72, 95% CI 1.32 
to 2.24, p<0.001) and macrosomia (aOR 1.54, 95% CI 
Figure 4 Forest plot showing change in interpregnancy weight and the risk of caesarean section (CS) in all women relative 
to reference category (decrease in body mass index (BMI) defined as >−1 unit, moderate increase 1–3 units and substantial 
increase >3 units, reference category remained in same BMI category or changed by up to −2 to +2 units). aOR, adjusted OR. 
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0.94 to 2.50) compared with the reference category (no 
weight change). An increase in BMI is associated with a 
decreased risk of SGA (aOR 0.83, 95% CI 0.70 to 0.99, 
p=0.044). Results did not change after sensitivity anal-
yses removing low quality and studies with high bias. We 
believe this is the first systematic review and meta-analysis 
completed on the topic of interpregnancy weight change 
and adverse pregnancy outcomes in women from parity 
0 to 1. When results are further analysed according to 
prepregnancy BMI (<25 or >25 kg/m2), women with a 
normal prepregnancy BMI at first pregnancy are at higher 
risk of LGA (aOR 2.10, 95% CI 1.93 to 2.29) and GDM 
(aOR 3.10, 95% CI 2.74 to 3.50) compared with women 
with a BMI ≥25 kg/m2.
Interpretation of major findings
It is known that obesity is the most common risk factor 
for insulin insensitivity.30 A possible biological relation 
between obesity and adverse perinatal outcomes is the 
role of glucose and insulin insensitivity in pregnancy. 
The Pedersen Hypothesis, first suggested in 1952, stipu-
lates that a higher-than-normal level of glucose (the main 
energy substrate of the fetus) transferred via the placenta 
to the fetus stimulates the release of insulin and insu-
lin-like growth factors in the fetus, causing LGA infants 
or macrosomic births.31 This has been supported by 
research showing that high postprandial glucose concen-
tration predicts large birth weight and hypoglycaemia is 
associated with growth restriction.32
An overweight or obese pregnant woman has a 
50%–60% increase in insulin insensitivity compared with a 
normal weighted pregnant woman.33 Associated hypergly-
caemia for the infant, as well as an increase in the release 
of free fatty acids and triglycerides from adipose stores 
have been studied to be associated with increased birth 
weight and adiposity of the offspring.34 The reduction 
in insulin sensitivity as a result of interpregnancy weight 
gain may lead to higher levels of GDM, LGA, macrosomia 
and subsequent CSs. On the contrary, weight loss and its 
association with increased insulin sensitivity may there-
fore result in reduced numbers of GDM and increased 
numbers of SGA births. This may be as increased insulin 
sensitivity may cause less glucose to cross the placenta and 
thus there is an increased risk of SGA. Studies researching 
interpregnancy weight change in women over three 
consecutive pregnancies support this finding, with weight 
loss associated with an increased risk of low placental 
weight and SGA births.35 Studies have found that not all 
interpregnancy weight gain is attributed to weight gain in 
Figure 5 Forest plot showing change in interpregnancy weight and the risk of small-for-gestational-age (SGA) births in all 
women relative to reference category (decrease in body mass index (BMI) defined as >−1 unit, moderate increase 1–3 units and 
substantial increase >3 units, reference category remained in same BMI category or changed by up to −2 to +2 units). aOR, 
adjusted OR. 
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pregnancy: 0.45 kg can be credited to the trend of weight 
gain over time.36 Research has also shown that women 
with a BMI ≥25 kg/m2 before pregnancy experience 
greater increases in postpartum body weight, and weight 
change 12 months post partum is largely influenced by 
the prepregnancy body weight.37 Interpregnancy weight 
gain as a result of both insufficient gestational weight loss 
after the previous pregnancy, combined with the normal 
trend of weight gain over time may have an additive or 
synergistic effect and result in further lowering of insulin 
sensitivity.
strengths
We believe this is the first systematic review and meta-anal-
ysis completed on the topic of interpregnancy weight 
change and adverse pregnancy outcomes in women from 
parity 0 to 1 with singleton births. This review synthesised 
the available evidence on the association of interpreg-
nancy weight change, defined as the difference in BMI 
in early pregnancy between successive pregnancies, on 
major complications. The findings of 11 cohort studies 
showed that interpregnancy weight gain was strongly asso-
ciated with an increased risk of namely, GDM, CS and large 
birthweight babies among all women regardless of initial 
BMI status, and a decrease in risk of SGA. Conversely, 
interpregnancy weight loss was strongly associated with a 
reduced risk of GDM, and large birth eight in the second-
born offspring, an increase in risk of SGA, but no detect-
able association with the rate of CS. The criteria outlined 
in the PRISMA statement and the Cochrane Handbook 
for Systematic Reviews of Intervention was adhered to, 
and this can be seen in table 2 (see online supplemen-
tary appendix 4). Furthermore, the MOOSE checklist of 
recommendations for reporting meta-analyses of observa-
tional studies was followed. Results did not change even 
after sensitivity analyses of high methodological quality 
studies.
Studies included in this review were cohort studies with 
generally large sample sizes, resulting in a large pooled 
sample of almost 1 million women. The strengths of using 
these studies meant that they are population-based, with a 
generally representative population. Outcomes were clas-
sified in the same way in each study and for most of the 
outcomes it is objectively defined to classify if the outcome 
occurred or not, reducing a possible bias of assessment 
of outcome. In addition to this, the reliability of medical 
records has shown good level of both inter-rater and intr-
arater reliability.38 This review used two different ways 
of analysing the quality of studies and possible sources 
of bias—the NOS and the Cochrane analysis of bias. All 
studies had at least 4 stars on the NOS, and sensitivity 
analysis was performed to remove low-quality studies or 
studies with a high bias. All studies used aORs to adjust 
for confounding factors such as age, race, interpregnancy 
interval and previous adverse outcome in first pregnancy.
Parity and previous diabetes mellitus were adjusted 
for in this review, which included only primiparous 
women (from parity 0 to 1) with no previous history of 
type 2 diabetes mellitus (T2DM). Compared with low 
multiparity, primigravid women have different risks and 
complications while higher parity (parity 4 upwards) has 
been associated with increased obstetric complications 
and neonatal morbidity.39 Furthermore, T2DM during 
pregnancy is associated with higher risks of stillbirth, 
perinatal mortality and congenital malformations.40 
Excluding these factors and taking into account that all 
papers included in this review were adjusted for multiple 
confounding variables means that it is less likely that the 
results are due to confounding or systematic bias and 
more likely to reflect genuine causality. Furthermore, this 
review aimed to minimise heterogeneity in several ways: 
each study was assessed to determine if confounding 
factors were appropriately recognised and adjusted for, 
weight change was stratified into three categories in order 
to effectively combine results that could be compared and 
sensitivity analysis was carried out by removing low-quality 
studies with a high level of bias.
limitations
Originally in the search strategy and PROSPERO registra-
tion other outcomes were aimed to be included (preterm 
birth, pre-eclampsia, perinatal death); however, there was 
a lack of relevant data and low-quality studies linked to 
these outcomes and thus these outcomes were excluded 
from this report. Other deviations from the protocol 
included the population definition being expanded to 
all women and not just overweight/obese women, which 
enhances the external validity of the study. Subgroup 
analyses was not included in the registration as we did 
not have details of the analyses at the time of registration 
and this addition provide further nuance on our find-
ings. Despite attempts to limit heterogeneity as described 
above, the high heterogeneity means that it may be 
misleading to combine results to provide an average esti-
mate of exposure, especially in light of the relatively small 
sample sizes in each outcome. Conclusions should there-
fore be interpreted with caution and considered largely 
hypothesis-generating. The effect of confounders could 
not be assessed by comparing unadjusted ORs and aORs, 
as unadjusted data were not available nor was it possible 
to calculate based on the available data. A random-effects 
model was used rather than a fixed-effect model to assess 
heterogeneity in the meta-analysis as it considers in-be-
tween study variation. Further statistical analysis to assess 
heterogeneity such as meta-regression was not performed 
due to the limited number of studies for each outcome; 
however, possible sources of heterogeneity are listed in 
table 4. Many of the studies report missing data and have 
categorised BMI change differently (eg, units, WHO 
groups or percentages), making it difficult to combine 
data in a meaningful and objective way. However, this 
was addressed with subgroup analysis and by stratifying 
weight change into categories. The use of observational 
cohort studies means that it is very difficult to adjust 
for all possible confounding factors, leading to an inev-
itable heterogeneity between studies. Publication bias 
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could not be assessed due to the small amount of studies 
in each primary outcome, with most of the outcomes 
having between two and five studies in each category. 
It has been suggested that <10 studies is not adequate 
in order to complete a funnel plot and would thus be 
underpowered.41
BMI is closely linked to lifestyle factors, diseases and 
genetic traits that are correlated with the outcome 
of pregnancy. Although studies adjusted for multiple 
confounding factors, there are additional confounders 
that could affect results that were not adjusted for, 
including breast feeding, diet, exercise and genetics. 
In addition, the effect of obesity may be confounded 
by several comorbidities that are possibly undiagnosed. 
Breast feeding may be a possible confounding factor in 
interpregnancy weight change as women who breast feed 
have less weight post partum, which is thought to be due 
to the high calorie usage during breast feeding, however 
this is contentious.42 The lack of information regarding 
diet and exercise means that the reduced risk of adverse 
outcomes in pregnancy may not be due to the weight loss 
but due to other aspects that are changed in a healthier 
lifestyle. Furthermore, interpregnancy interval and gesta-
tional weight gain were adjusted for in some studies, but 
the effect of these should not be underestimated. The 
shorter the interpregnancy interval, the higher the risk of 
LGA.43 The shorter the time between pregnancies or the 
more gestational weight gain, the more difficult it may be 
for women to lose the weight gained from the previous 
pregnancy. All future studies should adjust for interpreg-
nancy interval. Gestational weight gain is responsible 
for interpregnancy weight gain after the first pregnancy, 
but is a potential mediator in the second pregnancy and 
therefore it is questionable whether it should be adjusted 
for.
This review focused on singleton births from parity 0 
to 1, with all of the studies coming from high-income 
Western countries. This limits the generalisability of the 
conclusions to lower-income countries. Even though this 
review did exclude women with previous T2DM, it should 
be noted that due to the lack of a universal screening for 
GDM, some women with GDM may have been missed. 
This is difficult to assess and control, and due to the 
controversy surrounding screening for GDM and the lack 
of good quality evidence-based data, it has been unable 
to determine whether or not screening would have an 
important effect on adverse pregnancy outcomes.44
Future research
This review highlights that observational studies can help 
give direction for future research. To help clarify the 
association between interpregnancy weight change and 
adverse pregnancy outcomes, a precise way of measuring 
BMI change needs to be implemented and subgroup defi-
nitions should be consistent. Due to the problems with 
low rate of outcome, large studies free of bias associated 
with recall and self-report need to be undertaken that 
adhere to STrenghtening the Reporting of OBservational 
studies in Epidemiology (STROBE) guidelines and Inter-
national Consortium for Health Outcomes Measurement 
(ICHOM) standards. Future researchers should also 
consider the possible synergistic and additive effect of 
normal weight gain over time combined with insufficient 
postpartum weight loss and how it can affect pregnancy 
outcomes.
Large-scale studies on specific classes of obesity should 
be conducted to study the rate of weight change and if it 
affects the magnitude of association. The National Insti-
tute for Health Research submitted a call for research 
regarding weight management after pregnancy, stating 
that excessive gestational weight gain or postpartum 
weight retention may be cumulative over successive 
pregnancies.45 The Supporting Women with Postnatal 
Management feasibility study is aiming to study women 
allocated to an intervention (weight management group) 
or control group at 36 weeks of pregnancy and followed up 
12 months postnatally. This will be one of the first studies 
to look at postnatal intervention in weight control in the 
UK.46 Furthermore, Slimming World undertook a study 
in Cardiff called Health Eating and Lifestyle in Pregnancy 
to look at the benefits of behaviour changes and weight 
management during pregnancy in the UK. The study was 
underpowered but healthy eating and lifestyle interven-
tion was acceptable to help women control their weight 
change during pregnancy and post partum.47 Other feasi-
bility studies such as Pregnancy and Weight Monitoring 
are currently underway and evaluation of the efficacy of 
these interventions is expected in the future.48
Implications for policy makers and clinicians
The NICE postnatal guidelines currently suggest that 
women with a BMI >30 kg/m2 at the 6–8 weeks postnatal 
check are referred for advice regarding weight loss. This 
review provides some evidence to suggest that postnatal 
weight interventions are needed, as even moderate 
changes in interpregnancy BMI can lead to increased 
Table 4 Possible reasons to explain high heterogeneity (I2) 
found in the review
Possible sources of 
heterogeneity Example
Classification of body mass 
index change
Units (kg/m2), WHO groups 
(underweight, obese)
Different population design Sources of data varied, 
locations of studies varied
Differences in study design Use of self-report for height 
and weight
Missing data Missing data in original 
studies could not be 
controlled for
Small number of studies for 
each outcome
Between two and five studies 
for each outcome
Unknown factors (residual 
confounding variables)
Breast feeding, family history, 
diet, exercise
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risks of adverse pregnancy outcomes for the mother and 
baby. However, the effect of weight loss on increased risk 
of SGA should not be forgotten.
The Institute of Medicine has introduced optimal 
weight gain for BMI-specific ranges in pregnancy, although 
NICE has recommended that these guidelines should 
be researched to see if they are appropriate for the UK 
population.49 Based on the results of this review, it can be 
suggested that clinicians should be aware of the risk in 
women whose BMI has changed after their first pregnancy. 
Particularly women who wish to conceive again shortly 
after birth of their first child should be monitored after 
pregnancy to attempt to keep BMI change to a minimum. 
Importantly, women who are at a healthy weight are not 
without risk. Therefore, monitoring gestational weight 
change is important in preventing adverse outcomes in 
pregnancy, and interpregnancy weight change can also 
influence maternal and fetal outcomes.
COnClusIOn
This study is the first systematic review and meta-analysis 
to assess the association of interpregnancy weight change 
on five adverse pregnancy outcomes. The results show that 
interpregnancy weight gain increases the risk of GDM, CS 
and LGA, but lowers the risk of SGA, while weight reduction 
lowers the risk of GDM and LGA and increases the risk of 
SGA. In particular, it is noted that weight gain from normal 
weight is more detrimental than from a higher weight 
in regard to GDM, LGA and CS. Keeping weight stable 
between consecutive conceptions is important in order to 
lower the risk of adverse pregnancy outcomes. However, 
further research is needed to substantiate the evidence 
presented in this review.
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